Sci ., 21 , E6635, doi: 10.3390/ijms21186635
The association between GLP-1 RA initiation and first-time diagnoses may suggest that healthcare providers are actively screening for conditions like T2D and sleep apnea following the prescription
Try to lower stress and prioritize sleep
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which were initially approved for the treatment of type 2 diabetes (T2D) and obesity, have cardiovascular benefits that extend beyond glycaemic control
When people go off these drugs, they typically regain weight
reports honoraria from Novo Nordisk, Eli Lilly, Medscape, ViiV Healthcare and International Medical Press, and advisory board and consultancy work for Novo Nordisk, Eli Lilly, Pfizer, Gila Therapeutics, Epitomee Medical and ViiV Healthcare